• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对原发性体液免疫缺陷患者快速输注静脉注射免疫球蛋白(商品名:Sandoglobulin)

Rapid infusion of Sandoglobulin in patients with primary humoral immunodeficiency.

作者信息

Schiff R I, Sedlak D, Buckley R H

机构信息

Department of Pediatrics, Duke University Medical Center, Durham, N.C. 27710.

出版信息

J Allergy Clin Immunol. 1991 Jul;88(1):61-7. doi: 10.1016/0091-6749(91)90301-4.

DOI:10.1016/0091-6749(91)90301-4
PMID:1906490
Abstract

We studied 16 patients with primary disorders of humoral immunity to determine the practicality of infusing intravenous gamma globulin at rates of infusion and concentrations higher than the 4 mg/kg/min and 6% currently recommended. In the first portion of the study, the concentration of Sandoglobulin was increased from 6% to 12%. In the second portion, the flow rate was increased to 5 mg/kg/min, and if no reactions occurred, the time of each successive infusion was decreased by 10 minutes until infusions were completed in 15 to 20 minutes or vasomotor reactions occurred. Thirteen of the 16 patients completed the study; six patients achieved reaction-free rates greater than 15 mg/kg/min, and the other patients achieved rates ranging from 7.1 to 12 mg/kg/min. Seven patients had infusion times less than 30 minutes, with four patients completing infusions in 15 minutes. In the 13 patients who completed the study, there were 14 reactions in 159 infusions, mostly fever and chills, and often at the end or after the infusion. Only one infusion could not be completed because of an adverse reaction. Three patients were not able to complete the study because of adverse reactions; there were seven reactions in 11 infusions in these three patients, although none of the reactions were considered serious. Overall, in this study, most immunodeficient patients (13/16) were able to tolerate infusion rates of Sandoglobulin two to 10 times higher than the standard rates now recommended. The maximal rate of infusion must be individualized, but for carefully selected patients, infusions of 400 mg/kg can be completed in 1 hour or less.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

我们研究了16例体液免疫原发性疾病患者,以确定输注静脉注射丙种球蛋白的速率和浓度高于目前推荐的4mg/kg/分钟和6%的实用性。在研究的第一部分,桑球蛋白的浓度从6%提高到12%。在第二部分,流速提高到5mg/kg/分钟,如果没有反应发生,每次连续输注的时间减少10分钟,直到输注在15至20分钟内完成或出现血管舒缩反应。16例患者中有13例完成了研究;6例患者的无反应速率大于15mg/kg/分钟,其他患者的速率在7.1至12mg/kg/分钟之间。7例患者的输注时间少于30分钟,4例患者在15分钟内完成输注。在完成研究的13例患者中,159次输注中有14次反应,主要是发热和寒战,且通常在输注结束时或之后。只有一次输注因不良反应未能完成。3例患者因不良反应未能完成研究;这3例患者在11次输注中有7次反应,尽管没有一次反应被认为是严重的。总体而言,在本研究中,大多数免疫缺陷患者(13/16)能够耐受比目前推荐的标准速率高2至10倍的桑球蛋白输注速率。最大输注速率必须个体化,但对于精心挑选的患者,400mg/kg的输注可以在1小时或更短时间内完成。(摘要截短至250字)

相似文献

1
Rapid infusion of Sandoglobulin in patients with primary humoral immunodeficiency.对原发性体液免疫缺陷患者快速输注静脉注射免疫球蛋白(商品名:Sandoglobulin)
J Allergy Clin Immunol. 1991 Jul;88(1):61-7. doi: 10.1016/0091-6749(91)90301-4.
2
Immune globulin (human) 10 % liquid: a review of its use in primary immunodeficiency disorders.免疫球蛋白(人)10%溶液:在原发性免疫缺陷病中的应用评价。
BioDrugs. 2013 Aug;27(4):393-400. doi: 10.1007/s40259-013-0044-3.
3
Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study.皮下注射 IgPro20 在原发性免疫缺陷患者高输液参数下的安全性和耐受性:来自 HILO 研究泵辅助给药队列的研究结果。
J Clin Immunol. 2021 Feb;41(2):458-469. doi: 10.1007/s10875-020-00912-5. Epub 2021 Jan 6.
4
A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiency.在原发性免疫缺陷病的治疗中,10%即用型静脉注射用人免疫球蛋白相较于冻干产品具有潜在的经济优势。
Clin Exp Immunol. 2007 Dec;150(3):437-41. doi: 10.1111/j.1365-2249.2007.03520.x. Epub 2007 Oct 22.
5
Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency.伊朗原发性免疫缺陷患者预防性静脉注射免疫球蛋白的不良反应
Ann Allergy Asthma Immunol. 2004 Jan;92(1):60-4. doi: 10.1016/S1081-1206(10)61711-5.
6
Intrainfusion and postinfusion adverse events related to intravenous immunoglobulin therapy in immunodeficiency states.免疫缺陷状态下与静脉注射免疫球蛋白治疗相关的输注期间及输注后不良事件。
Allergy Asthma Proc. 2006 Nov-Dec;27(6):532-6. doi: 10.2500/aap.2006.27.2917.
7
Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.静脉或皮下替代治疗剂量等效转换后,Hizentra(®) 在原发性免疫缺陷患者中的疗效和安全性。
Clin Immunol. 2011 Oct;141(1):90-102. doi: 10.1016/j.clim.2011.06.002. Epub 2011 Jun 12.
8
Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin.在接受静脉注射免疫球蛋白的一大群先天性免疫缺陷患者中出现的不良反应。
Clin Immunol. 2021 Sep;230:108826. doi: 10.1016/j.clim.2021.108826. Epub 2021 Aug 19.
9
Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.在一个包含1765次输注的前瞻性队列中,静脉注射免疫球蛋白的即时输注相关不良反应。
Int Immunopharmacol. 2014 Dec;23(2):442-6. doi: 10.1016/j.intimp.2014.09.015. Epub 2014 Sep 22.
10
Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases.Intraglobin-F与Gamimune-N、Sandoglobulin和Gammagard在原发性免疫缺陷疾病患者中的安全性和有效性的多中心交叉比较。
J Clin Immunol. 1997 Jan;17(1):21-8. doi: 10.1023/a:1027380210989.

引用本文的文献

1
Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes.原发性免疫缺陷病的新兴模式:个体化免疫球蛋白剂量与给药方式以改善治疗效果
J Clin Immunol. 2017 Feb;37(2):190-196. doi: 10.1007/s10875-014-9990-x. Epub 2014 Jan 30.
2
Safety and tolerability of increased rate of infusion of intravenous immunoglobulin G, 10% in antibody-deficient patients.抗体缺乏患者中10%静脉注射免疫球蛋白G输注速率增加的安全性和耐受性
J Clin Immunol. 2006 May;26(3):284-90. doi: 10.1007/s10875-006-9014-6. Epub 2006 May 31.
3
Intravenous immune globulin in primary immunodeficiency.
原发性免疫缺陷病中的静脉注射免疫球蛋白
Clin Exp Immunol. 1994 Jul;97 Suppl 1(Suppl 1):11-5.
4
Rapid intravenous immunoglobulin infusions in children with idiopathic thrombocytopenic purpura.特发性血小板减少性紫癜患儿快速静脉输注免疫球蛋白
Eur J Pediatr. 1994 Nov;153(11):862. doi: 10.1007/BF01972900.